Abstract 997P
Background
Microvascular invasion (MVI) is an independent poor factor for early recurrence (ER) and long-term outcomes in hepatocellular carcinoma (HCC) after hepatectomy. A practical, convenient, and accurate risk classifications is urgently needed to predict ER risk in HCC patients with MVI and to guide those patients to choose suitable adjuvant therapies to reduce postoperative recurrence risks and prolong long-term survival.
Methods
Data of 440 HCC patients with MVI after curative hepatectomy were retrospectively reviewed. They were randomly divided into a training set and a validation set. Kaplan-Meier curves and Cox regression analyses were used to identify independent prognostic factors of ER. Classification and regression tree (CART) analysis was used to develop ER risk classification in the training set and verified in the validation set.
Results
Multivariate analysis revealed that seven factors, namely, hepatitis B virus deoxyribonucleic acid load, tumor size, Edmondson-Steiner grade, MVI classification, satellite nodules, Ki67 positive index, and cytokeratin 19 expression were independent risk indexs for ER in HCC patients with MVI. The CART strategy showed a good concordance statistics of 0.77 in predicting ER risk, and had a better net benefit and a wider threshold probability range, as well as had a good agreement between the predicted value and actual observed value. The area under the time-dependent receiver operating characteristic curve of the CART strategy in predicting 1-, 3-, and 5-years recurrence-free survival (RFS) were 0.75, 0.78, and 0.84, respectively, and the corresponding overall survival (OS) were 0.74, 0.74, and 0.72, respectively, which were all significantly higher than other eight commonly classic HCC system stages (BCLC stage, Okuda stage, TNM stage, CNLC stage, French stage, CLIP score and JIS score). The ER, RFS and OS were greatly discrepancies between patients that had been stratified into three risk groups. Similar results were obtained in the validation set.
Conclusions
The CART strategy achieved optimal prediction for ER, RFS and OS for HCC patients with with MVI after curative hepatectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the National Natural Science Foundation of China (NO. 82060427, 82103297), Guangxi Key Research and Development Plan (NO. GUIKEAB19245002), Guangxi Scholarship Fund of Guangxi Education Department, Guangxi Natural Science Foundation (NO. 2020GXNSFAA259080).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18